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Objectives:  To  assess  the  feasibility  of whole-body  magnetic  resonance  imaging  (WB-MRI)  including
diffusion-weighted  whole-body  imaging  with  background-body-signal-suppression  (DWIBS)  for the
evaluation  of distant  malignancies  in head  and neck  squamous  cell carcinoma  (HNSCC);  and  to  compare
WB-MRI  ﬁndings  with 18F-ﬂuorodeoxyglucose  positron  emission  tomography/computed  tomography
(18F-FDG-PET/CT)  and  chest-CT.
Methods:  Thirty-three  patients  with  high  risk  for metastatic  spread  (26 males;  range  48–79 years,  mean
age  63  ±  7.9  years  (mean  ±  standard  deviation)  years)  were  prospectively  included  with  a  follow-up  of
six months.  WB-MRI  protocol  included  short-TI  inversion  recovery  and  T1-weighted  sequences  in the
coronal  plane  and  half-fourier  acquisition  single-shot  turbo  spin-echo  T2 and  contrast-enhanced-T1-
weighted  sequences  in the axial  plane.  Axial  DWIBS  was  reformatted  in  the  coronal  plane.  Interobserver
variability  was  assessed  using  weighted  kappa  and  the  proportion  speciﬁc  agreement  (PA).
Results:  Two  second  primary  tumors  and  one  metastasis  were  detected  on  WB-MRI.  WB-MRI  yielded
seven  clinically  indeterminate  lesions  which  did not  progress  at follow-up.  The  metastasis  and  one  sec-
ond  primary  tumor  were  found  when  combining 18F-FDG-PET/CT  and  chest-CT  ﬁndings.  Interobserver
18variability  for  WB-MRI  was   = 0.91  with  PA ranging  from  0.82  to 1.00.  For F-FDG-PET/CT    could  not
be  calculated  due  to a constant  variable  in  the table  and PA  ranged  from  0.40  to  0.99.
Conclusions:  Our  WB-MRI  protocol  with  DWIBS  is  feasible  in the  work-up  of  HNSCC  patients  for  detection
and  characterization  of  distant  pathology.  WB-MRI  can  be  complementary  to 18F-FDG-PET/CT,  especially
in  the detection  of non 18F-FDG  avid  second  primary  tumors.
© 2014 Elsevier  Ireland  Ltd.  All  rights  reserved.. IntroductionIn head and neck squamous cell carcinoma (HNSCC) patients,
–18% present with clinically identiﬁed distant spread of disease,
hile autopsy incidences have been reported to be up to 57% [1].
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720-048X/© 2014 Elsevier Ireland Ltd. All rights reserved.Only palliative treatment remains when distant metastases are
present in patients with HNSCC. Therefore, efforts should be made
to detect distant metastases and avoid futile treatment.
Screening for distant metastases is currently done on a routine
basis by means of 18F-ﬂuorodeoxyglucose positron emission tomo-
graphy/computed tomography (18F-FDG-PET/CT) in combination
with a diagnostic chest-CT in patients at high risk of developing dis-
tant metastases. Most metastases or second primary tumors (SPT)
develop within 15 months after the end of treatment with curative
intent, despite negative screening on 18F-FDG-PET/CT. Since false
negative rates are up to 50%, room for improvement remains [1–5].Due to several technical improvements, it is now clinically fea-
sible to perform high-resolution whole-body magnetic resonance
imaging (WB-MRI) protocols in less than one hour. In HNSCC
patients, WB-MRI showed a promising role for the evaluation of
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Table  1
Patient characteristics of 33 HNSCC patients at whole-body MR imaging.
n Sex Age Location Recurrence TNM Previous treatment
1 Male 58 Hypopharynx Locoregional recurrence T4N3 Chemoradiation
2  Male 68 Hypopharynx Second primary tumor T4N2 CO2 laser excision
3  Male 57 Larynx Primary tumor T4N0 –
4  Male 57 Oropharynx Primary tumor T2N2 –
5  Female 69 Oropharynx Locoregional recurrence T3N2 Chemoradiation
6  Female 73 Larynx Locoregional recurrence T4N2 Excision + neck dissection + chemoradiation
7  Male 58 Oropharynx + oropharynx Primary tumors T2N1 + T2N1 –
8  Male 74 Nasopharynx Second primary tumor T1N2 Radiotherapy + excision + neck
dissection + postoperative radiotherapy
9  Male 48 Oropharynx Primary tumor T4N2 –
10  Male 55 Oropharynx Second primary tumor T3N1 Neck dissection + radiotherapy
11  Male 63 Oropharynx Primary tumor T3N2 –
12  Male 65 Oral cavity Locoregional recurrence T1N0 Excision + neck dissection + radiotherapy
13  Male 70 Oropharynx Locoregional recurrence T2N1 Radiotherapy
14  Male 64 Hypopharynx Primary tumor T2N2 –
15  Male 59 Larynx Locoregional recurrence T2N2 Chemoradiation + excision
16  Male 62 Hypopharynx + oropharynx Locoregional recurrence T3N2 + T2N2 Chemoradiation
17  Female 67 Oral cavity Second primary tumor T4N0 Excision + neck dissection
18  Male 59 Tongue Locoregional recurrence T3N0 Radiotherapy
19  Male 75 Hypopharynx Second primary tumor T3N0 Radiotherapy
20  Male 57 Oral cavity Second primary tumor T2N0 Excision + neck dissection + radiotherapy
21  Male 50 Oropharynx Primary tumor T4N2 –
22  Female 51 Larynx Locoregional recurrence T2N0 Radiotherapy
23  Female 69 Oropharynx Locoregional recurrence T2N0 Chemoradiation
24  Male 61 Oropharynx Primary tumor T1N2 Radiotherapy + excision + neck dissection
25  Male 63 Oropharynx Third primary T3N0 –
26  Female 52 Larynx Locoregional recurrence T2N2 Chemoradiation
27  Male 59 Oropharynx Primary tumor T3N2 –
28  Male 66 Oropharynx Primary tumor T2N2 –
29  Male 59 Oropharynx Primary tumor T1N2 –
30  Male 66 Oral cavity Recurrence T2N0 Radiotherapy + neck dissection + excision
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etastatic spread of disease despite variations in diagnostic accu-
acy of WB-MRI versus 18F-FDG-PET/CT [6–8].
In addition to conventional WB-MRI, diffusion-weighted imag-
ng (DW-MRI) has shown potential. In order to deal with motion
rtifacts, Takahara et al. developed diffusion-weighted whole-
ody imaging with background body signal suppression (DWIBS).
his sequence allows for the acquisition of DW-MRI under free-
reathing [9]. The addition of DWIBS might improve the accuracy
f WB-MRI to detect distant metastases [10–12].
The reported imaging sequences as well as imaging planes are
uite variable [3,4,6–8,10–18]. As the addition of either DW-MRI
r contrast-enhanced (CE) sequences may  improve the outcome of
iagnostic interpretation, the value of these modalities needs to
e clariﬁed further. In addition, the choice of the imaging plane
e.g. axial versus coronal) has considerable effect on the duration
f the scan, and potentially on the interpretation of the images as
ell. Therefore, tailor-made imaging protocols may  optimize the
erformance of WB-MRI.
The purpose of our study therefore was to prospectively assess
he feasibility of WB-MRI including DWIBS for the evaluation of
istant malignancies in HNSCC patients with high risk factors for
he presence of metastatic disease; and to compare MRI  ﬁndings
ith 18F-FDG-PET/CT and chest-CT.
. Materials and methods
.1. Study population
This prospective study was performed in a tertiary refer-
al center for HNSCC between August 2009 and June 2012.
nclusion criteria comprised histopathologically proven HNSCC;
lanned extensive treatment with curative intent (surgery and/or
adiotherapy with or without chemotherapy); planned routineT4N2 –
T2N0 Excision + neck dissection
rrence T2N0 Neck dissection + postoperative radiotherapy
screening for the presence of distant metastases by means of 18F-
FDG-PET/CT and chest-CT, i.e., at least one of the high risk factors
for the development of distant metastases, as previously deﬁned
by De Bree et al. (clinically three or more lymph node metastases;
bilateral lymph node metastases; lymph node metastases of 6 cm
or larger; low jugular lymph node metastases; locoregional recur-
rence or second primary tumor) [5]; and an age of 18–80 years.
Exclusion criteria were pregnancy and contraindications for MRI.
After approval of the local institutional review board and informed
consent, 33 patients were included. For more detailed patient char-
acteristics we refer to Table 1.
Whole-body 18F-FDG-PET/CT and WB-MRI were performed at
random order as dictated by logistics (time difference: mean
15.8 ± 11.3 days).
2.2. Whole-body-MRI
MR  imaging was performed on a 1.5T-system (Magnetom
Avanto; Siemens, Erlangen, Germany), using a total imaging matrix
(TIM) coil system combined with dedicated coils. WB-MRI up to the
upper femora was  performed with the acquisition of a T1-weighted
sequence in the coronal plane; a short-tau inversion recovery (STIR)
sequence in the coronal plane; an axial T2-weighted sequence cov-
ering the entire body; dedicated axial liver sequences covering the
upper abdomen in the axial plane, including in- and opposed phase
T1 gradient-echo (GRE).
DWIBS was  acquired using with a 2D EPI sequence in the axial
plane and reformatted in the coronal plane and presented with
inverted signal intensity (b-value: 1000 s/mm2; number of aver-
ages: 2; fat saturation: SPAIR; parallel imaging: GRAPPA).
After administration of 0.2 mmol/kg gadoteric acid in 17
patients (Dotarem; Guerbet, Roissy, France) and of 0.15 mmol/kg
gadobutrol in 15 patients (Gadovist; Bayer Schering AG, Berlin,
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Table 2
MR Imaging protocol at 1.5T used in HNSCC patients (DW diffusionweighted, EPI echo-planar imaging, FLASH fast low angle shot, FS fat saturation, GRE gradient echo, HASTE
half-Fourier acquisition single-shot turbo spin-echo, STIR short-TI inversion recovery, TSE turbo spin echo, VIBE volumetric interpolated breath-hold).
Sequence Region TR (ms) TE (ms) Matrix FOV (mm)  Slices Thickness (mm) Flip
angle
Scan time
(min:s)
Pre-contrast Cor STIR Whole body 6000 62 320 × 224 500 31 4 150 10:00
Cor  T1 TSE Whole body 520 9.1 320 × 256 500 31 4 150 9:00
Ax  DW-MRI-EPI Whole body 8200 66 128 × 88 500 60 4 90 9:00
Ax  T2 TSE Head and Neck 4750 108 448 × 252 250 28 5 180 1:41
Ax  T1 GRE Liver 100 2.38/4.76 256 × 154 350 20 6 70 0:32
Ax  HASTE-T2 Thorax-pelvis 1000 65 256 × 165 500 20 8 150 0:22
Ax  VIBE FS Liver 5.46 2.38 256 × 135 450 64 3 10 0:21
Postcontrast Ax VIBE FS Liver 5.46 2.38 256 × 135 450 64 3 10 1:30
Ax  T1 TSE Head and Neck 755 9.5 320 × 256 250 28 5 150 1:31
256 ×
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ermany) dynamic contrast-enhanced fat-suppressed volumet-
ic interpolated breath-hold (VIBE) T1-weighted sequences in the
rterial and delayed venous phases and a T1-weighted sequence
overing the entire body were acquired in the axial plane. One
atient did not receive MR-contrast due to renal failure. An
verview of the scanned anatomic regions and sequences is pro-
ided in Tables 2 and 3. Total examination time approximated
0 min, with scan time being 35 min.
.3. 18F-FDG-PET/CT
Thirty-one patients underwent a PET/low-dose CT (LD-CT) scan
fter a 6 h fast period and adequate hydration. The examina-
ion was performed from mid-thigh to skull vertex, 60 min  after
ntravenous administration of 250–370 MBq 18F-FDG. Scans were
cquired on a Gemini TOF-64 PET/CT scanner (Philips Medical Sys-
ems, Best, The Netherlands) with an axial ﬁeld of view of 18 cm.
ime of ﬂight (TOF) information was used during reconstruction.
able 3
chematic MR imaging protocol at 1.5 T used in HNSCC patients (CE contrast-enhanced
uppression, GRE gradient echo, HASTE half-Fourier acquisition single-shot turbo spin-echo
nterpolated breath-hold). 166 500 35 6 70 0:58
Total 34:55
Reconstructed images had an image matrix size of 144 × 144, a pixel
size of 4 mm × 4 mm and a slice thickness of 5 mm.  Low-dose-CT
was collected using a beam current of 30 to 50 mAs  at 120 keV. CT-
scans were reconstructed using an image matrix size of 512 × 512
resulting in pixel sizes of 1.17 mm × 1.17 mm and a slice thickness
of 5 mm.
In two  patients, examinations were performed at other insti-
tutions using Gemini TOF-64 and TOF-16 PET/CT scanners (Philips
Medical Systems, Best, The Netherlands), respectively.
2.4. Chest-CT
Chest-CT-scans were performed in 32 patients in the early
arterial phase on a fourth-generation CT-scanner (Somaton Plus;
Siemens, Erlangen, Germany) after intravenous contrast admin-
istration (Ultravist, Bayer Schering AG, Berlin, Germany) with a
reconstructed slice thickness of 5 mm.  In one patient only LD-CT
was performed.
, DWIBS diffusion-weighted whole-body imaging with background-body-signal-
, SE spin echo, STIR short-TI inversion recovery, TSE turbo spin echo, VIBE volumetric
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.5. Image analysis
All readers were aware of the HNSCC diagnosis, but blinded
o all other information, including the other imaging test
esults.
Whole-body-MRI images were analyzed for distant metastasis
nd SPT by two independent reviewers, with 4 and 2 years experi-
nce in WB-MRI. After separate analysis the ﬁnal decision was made
n consensus. The analysis consisted of two parts: (1) evaluation
f all conventional sequences without DWIBS; and (2) evaluation
fter DWIBS was added to the conventional sequences. Overall
mage quality and artifacts were assessed, per sequence, on a four-
oint Likert scale. For image quality: 1, inadequate; 2, adequate;
, good; 4, excellent. For artifacts: 1, none present; 2, irrelevant;
, diagnostically relevant; 4, marked. To complete the assessment
f image quality the sequences that best depicted the pathology
ere selected. Although the primary goal was screening for dis-
ant metastases, SPT and incidental ﬁndings were also registered.
ased on all MRI  ﬁndings the likelihood of metastasis and/or SPT
as scored on a three-point Likert scale: 1, yes; 2, clinically inde-
erminate, 3 = no. The presence of malignancy was suspected on
onventional WB-MRI in focal lesions with different signal intensi-
ies compared to the surrounding tissue. On the DWIBS malignancy
as suspected in case of abnormal signal intensity in focal
esions.
At ﬁrst, 18F-FDG-PET/CT images were analyzed independently
or distant metastasis and SPT by two reviewers with 12 and 4
ears’ experience in PET analysis. Again the ﬁnal decision was  made
n consensus. The likelihood of metastasis and/or SPT was scored
n a three-point Likert scale: 1, yes; 2, clinically indeterminate; 3,
o. Again the primary goal was screening on distant metastases,
ut SPT and other abnormalities were also registered. Lesions were
haracterized as suspicious for malignancy based on increased 18F-
DG uptake, incompatible with physiological 18F-FDG distribution,
ithin structures with an anatomical substrate on the (LD-)CT.
hest-CT was analyzed for distant metastasis and SPT by a radiolo-
ist with 7 years of experience. The likelihood of metastasis and/or
PT was scored on a three-point Likert scale: 1, yes; 2, clinically
ndeterminate; 3, no.
When the presence of metastasis and/or SPT based on imag-
ng was classiﬁed as ‘yes’ or ‘clinically indeterminate’, the ﬁnal
iagnosis regarding the presence of malignancy was  based on
istopathology or progression at six months of clinical follow-
p (i.e., clinical assessment in the outpatient clinic every two
onths).
.6. Statistical analysis
Interobserver variability for WB-MRI and 18F-FDG-PET/CT
as calculated with weighted kappa using Stata (version 11.2;
ollege Station, TX, USA) and with proportion speciﬁc agreement
sing Microsoft Excel (Microsoft Ofﬁce 2010, Microsoft, Redmond,
A,  USA) [19]. For the interpretation of weighted kappa the
ollowing cut-off values are used: ≤0.20 = poor, 0.21–0.40 = fair,
.41–0.60 = moderate, 0.61–0.80 = substantial, 0.81–1.00 = very
ood [20]. The proportion speciﬁc agreement consists of two parts:
ositive agreement (PA) and negative agreement (NA). These
wo numbers express the agreement on positive and negative
atings respectively. Two sets of positive and negative ratings
re calculated to deal with the ‘clinically indeterminate’ category
egarding the presence of malignancy. In the ﬁrst set clinically
ndeterminate is recoded into ‘yes’: PAclinically indeterminate = yes
nd NAclinically indeterminate = yes. In the second set ‘clinically inde-
erminate’ is recoded into ‘no’: PAclinically indeterminate = no and
Aclinically indeterminate = no.adiology 83 (2014) 1144–1151 1147
3. Results
3.1. MRI quality
One patient did not receive MR-contrast due to renal failure. All
other patients completed the entire protocol. Median image qual-
ity scores of the MR  sequences were: 4 (range, 3–4) for coronal
T1; 4 (range, 2–4) for coronal STIR; 3 (range, 3–4) for axial T2;
3 (range, 1–4) for axial T1 with contrast and 4 (range, 2–4) for
DWIBS, and for artifacts: 1 (range, 1–2) for coronal T1; 2 (range,
1–3) for coronal STIR; 1 (range, 1–2) for axial T2; 1 (range, 1–4) for
axial T1 with contrast and 1 (range, 1–3) for DWIBS. The coronal
STIR was indicated to be most informative in 19 patients, coronal
DWIBS in 24 patients and axial T2 in 17 patients by both review-
ers.
3.2. Comparison between WB-MRI, 18F-FDG-PET/CT and chest-CT
One patient had a distant HNSCC metastasis (lung; maximum
axial diameter: 8 mm)  (Fig. 1) and two  had SPT (renal cell carcinoma
(RCC); maximum axial diameter: 80 mm,  and a neuroendocrine
tumor with liver metastases; maximum axial diameter: 20 mm)
(Fig. 2). On WB-MRI, without DWIBS, this metastasis was sus-
pected and both SPTs were found. On DWIBS these three lesions
all showed diffusion restriction, this conﬁrmed the presence of
malignancy. In another patient DWIBS aided in favor of the cor-
rect ﬁnal diagnosis: the addition of DWIBS changed the conclusion
regarding the presence of malignancy from ‘clinically indetermi-
nate’ to ‘no’ in a benign cervical bone lesion. Seven lesions on
WB-MRI including DWIBS were classiﬁed as clinically indeter-
minate: two  vertebral lesions (one had a negative biopsy and
both did not progress at follow-up), four thoracic lesions (all
regressed at follow-up) and one pancreatic lesion (did not progress
at follow-up). An adrenal lesion was correctly qualiﬁed as benign,
whereas diagnostic chest-CT was  equivocal. The lesion did not
show 18F-FDG uptake on 18F-FDG-PET/CT and did not progress
at follow-up. Other relevant incidental ﬁndings detected on WB-
MRI  were bone infarction, cholelithiasis, (old) brain infarction,
scoliosis, hemochromatosis and atelectasis. WB-MRI was cor-
rectly negative in 25 patients, after the addition of DWIBS in 24
patients.
On 18F-FDG-PET/CT the HNSCC lung metastasis was also
detected, but not the SPTs. Two  lesions, a focal lung lesion and a
vertebral bone lesion, were classiﬁed as clinically indeterminate.
18F-FDG-PET/CT was correctly negative in 30 patients. On  chest-
CT the HNSCC lung metastasis and the RCC were identiﬁed. Eight
lesions were classiﬁed as clinically indeterminate: four focal lung
lesions, two lymph nodes, one bone lesion and a liver lesion. None
of these lesions did progress at follow-up. Chest-CT was  correctly
negative in 25 patients.
The clinical standard of practice (18F-FDG-PET/CT and chest-CT)
yielded metastasized HNSCC in one patient and RCC in another. One
vertebral bone lesion remained clinically indeterminate using the
clinical standard of practice. This lesion did not progress at follow-
up.
The interobserver agreement for WB-MRI was
very good ( = 0.91, PAclinically indeterminate = yes = 0.82;
NAclinically indeterminate = yes = 0.96; PAclinically indeterminate = no = 1.00
and NAclinically indeterminate = no = 1.00). For 18F-FDG-PET/CT
weighted kappa could not be calculated. This is because
the table contained a constant variable, which made
it impossible to calculate weighted kappa. Proportion
speciﬁc agreement was: PAclinically indeterminate = yes = 0.40;
NAclinically indeterminate = yes = 0.98; PAclinically indeterminate = no = 0.67
and NAclinically indeterminate = no = 0.99.
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Fig. 1. Coronal and axial images in a 62-year old male with a lung metastasis in the apex of the left lower lobe (arrow). (a) Coronal STIR, (b) coronal T1, (c) DWIBS, (d) axial
contrast-enhanced T1, (e) axial fused 18F-FDG-PET/CT and (f) axial chest-CT. Mainly due to diffusion-restriction on the coronal DWIBS this lesion is suspected to be malignant.
The  lesion demonstrates 18F-FDG uptake and on chest-CT a solitary non-calciﬁed nodule is seen.
D.P. Noij et al. / European Journal of Radiology 83 (2014) 1144–1151 1149
Fig. 2. Images of a focal liver lesion (arrows) in a 68-year old male (multiple other lesions with identical characteristics not shown). (a) Coronal STIR, (b) DWIBS, (c) axial
HASTE-T2, (d) axial contrast-enhanced-T1-weighted VIBE in the arterial phase, (e) axial fused 18F-FDG-PET/CT and (f) axial LD-CT. Based on MR imaging ﬁndings this lesion
is  suspicious of malignancy, with neuroendocrine liver metastases as ﬁrst differential option. This has been conﬁrmed after biopsy. The high signal of the spleen on DWIBS
can  be considered physiological. The lesion is outside the ﬁeld of view of the diagnostic chest-CT. No uptake of 18F-FDG is seen. On low-dose CT a minimally hypodense lesion
is  seen only after visual correlation with MR-images. Therefore this lesion is regarded as undetected in further data-analysis.
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. Discussion
Various WB-MRI protocols have been compared to 18F-FDG-
ET/CT in the work-up of patients with (suspicion of) distant
etastases. In patients with colorectal and breast cancer Schmidt
t al. used an imaging protocol containing coronal STIR, coronal
1 and axial CE-T1. Radiological follow-up of at least 5 months
erved as a standard of reference [13,14]. In both studies WB-
RI  and 18F-FDG-PET/CT had comparable diagnostic accuracy in
etecting distant metastases. However, sensitivity and speciﬁcity
f WB-MRI to detect metastatic disease were variable: 95% and 92%
n breast cancer and 78% and 95% in colorectal cancer respectively.
his suggests that the value of WB-MRI may  depend on the type of
alignancy and its metastatic pattern. Ohno et al. found the combi-
ation of conventional WB-MRI and DW-MRI to have a diagnostic
ccuracy comparable to 18F-FDG-PET/CT for M-stage assessment
n non-small cell lung cancer, using a combination of imaging,
iopsy and at least 12 months of clinical follow-up as the refer-
nce standard. Sensitivity seemed to improve after the addition
f DW-MRI to conventional MRI  (from 60% to 70%) [18]. Heusner
t al. demonstrated high sensitivity (91%), but low speciﬁcity (72%)
f whole-body DW-MRI alone in the detecting breast cancer metas-
ases. Speciﬁcity was especially compromised in lymph nodes and
one lesions [16].
Taken together, these data suggest that imaging protocols con-
aining more MR-sequences than DW-MRI alone may  be preferable.
ompared to conventional DW-MRI, DWIBS has the advantage that
t allows for DW-MRI during free breathing [9]. Due to background
uppression small lesions are more easily detected on DWIBS [21].
In our study WB-MRI including DWIBS was superior to 18F-FDG-
ET/CT in the detection of SPT. In general SPTs in HNSCC mainly
merge in the head and neck area and the lungs [22]. 18F-FDG
ptake of RCC and neuroendocrine tumors is variable. Popula-
ions have been described where only 22% of the RCCs showed
ncreased 18F-FDG uptake [23,24]. Ng et al. performed two stud-
es in patients with advanced HNSCC. In a study of 79 patients with
dvanced HNSCC, Ng et al. reported that 18F-FDG-PET/CT showed
 (non-signiﬁcant) trend toward higher diagnostic capability than
onventional WB-MRI in detecting SPT below the clavicles (4/5 vs
/5). In another study in 150 patients with advanced HNSCC both
odalities were comparable. On WB-MRI a bronchoalveolar cell
arcinoma was detected, due to low 18F-FDG-uptake this was inter-
reted as inﬂammation on 18F-FDG-PET/CT. Using 18F-FDG-PET/CT
olon carcinoma was found, which was missed on WB-MRI. On both
odalities another SPT in the lung was detected [8,25].
Whole-body-MRI is considerably less expensive than 18F-FDG-
ET/CT. If WB-MRI can replace 18F-FDG-PET/CT, a substantial
eduction of health costs seems to be possible. Moreover, patients
ndergoing WB-MRI are not exposed to radiation as by 18F-FDG-
ET/CT. To replace 18F-FDG-PET/CT, WB-MRI needs to have at
east comparable diagnostic accuracy [26]. However, the biologi-
al information provided by the level of 18F-FDG uptake may  carry
rognostic relevance, and serial uptake measurements may  serve
s a predictive biomarker [27]. Hence, if the chest-CT information
roves to be redundant, PET-MRI might become the method of
hoice for personalized therapy.
In this pilot study we used a combination of STIR and T1 in the
oronal plane combined with T2 and dedicated liver sequences
n the axial plane. DWIBS was acquired in the axial plane and
eformatted in the coronal plane. By using this combination we
emonstrated the feasibility of WB-MRI not only to detect benign
nd malignant lesions, but also characterize them (e.g. heman-
iomas, renal cysts, bone infarction and hemochromatosis). In our
tudy population WB-MRI allowed for the detection of two non
8F-FDG avid malignancies. Whole-body MRI  yielded seven clin-
cally indeterminate lesions. In one of these lesions biopsy wasadiology 83 (2014) 1144–1151
performed. None of the clinically indeterminate lesions did
progress at follow-up. The addition of DWIBS aided in making the
correct ﬁnal diagnosis of a HNSCC lung metastasis and a benign cer-
vical bone lesion. Particular in bone and thoracic lesions WB-MRI
including DWIBS remained clinically inconclusive. On 18F-FDG-
PET/CT small thoracic lesions were difﬁcult to deal with and for
chest-CT lung nodules and mediastinal lymph nodes were chal-
lenging to characterize.
We  believe that there is a learning curve in the evaluation of WB-
MRI  including DWIBS. The addition of DWIBS to WB-MRI protocols
allows for fast image interpretation since it enables distinguish-
ment of malignant from benign tissue “at-a-glance” [28]. The use
of coronal images requires additional training as most radiologists
are more familiar with axial images. Incidental ﬁndings are more
frequently present than on 18F-FDG-PET/CT due to the higher soft
tissue detail on WB-MRI. Therefore some experience in WB-MRI is
necessary to deal with them properly.
Our study had some limitations. First, the incidence of distant
metastases was lower than would be expected according to our
inclusion criteria as deﬁned by de Bree et al. [5]; only one patient
had a distant metastasis and two patients demonstrated SPTs. Some
patients with high suspicion of distant metastases visualized on
18F-FDG-PET-CT refrained from WB-MRI. In the future this could
be prevented by performing all imaging on the same day. Other
patients refrained from WB-MRI due to claustrophobia. This limited
the possibilities for statistical analysis. Second, because this is a
pilot study, the number of patients was  limited. Therefore it is
necessary to prospectively validate this MR-protocol in a larger
population.
5. Conclusions
The presented WB-MRI protocol with DWIBS is feasible in the
work-up of patients with advanced HNSCC for the detection and
characterization of distant pathology; it allowed for the detection
of non 18F-FDG avid malignancies and can therefore be comple-
mentary to 18F-FDG-PET/CT.
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